Major reduction of rotavirus, but not norovirus, gastroenteritis in children seen in hospital after the introduction of RotaTeq vaccine into the National Immunization Programme in Finland.
about
A decade of norovirus disease risk among older adults in upper-middle and high income countries: a systematic reviewRotavirus vaccines in routine useVaccines for viral and bacterial pathogens causing acute gastroenteritis: Part I: Overview, vaccines for enteric viruses and Vibrio choleraeRotavirus vaccines: current status and future considerationsComplete nucleotide sequence of a norovirus GII.4 genotype: evidence for the spread of the newly emerged pandemic Sydney 2012 strain to China.Predominance of norovirus and sapovirus in Nicaragua after implementation of universal rotavirus vaccination.B-Cell Responses to Intramuscular Administration of a Bivalent Virus-Like Particle Human Norovirus Vaccine.Trivalent combination vaccine induces broad heterologous immune responses to norovirus and rotavirus in miceThe burden of norovirus disease in children in the European Union.Genetic susceptibility to norovirus GII.3 and GII.4 infections in Chinese pediatric diarrheal disease.Evaluation of the Intussusception Risk after Pentavalent Rotavirus Vaccination in Finnish InfantsPopulation-Based Incidence Rates of Diarrheal Disease Associated with Norovirus, Sapovirus, and Astrovirus in Kenya.Global age distribution of pediatric norovirus cases.Static and Evolving Norovirus Genotypes: Implications for Epidemiology and Immunity.Host Genetic Susceptibility to Enteric Viruses: A Systematic Review and Metaanalysis.Multicenter Evaluation of the Xpert Norovirus Assay for Detection of Norovirus Genogroups I and II in Fecal Specimens.Increased and prolonged human norovirus infection in RAG2/IL2RG deficient gnotobiotic pigs with severe combined immunodeficiency.Etiological Role and Repeated Infections of Sapovirus among Children Aged Less than 2 Years in a Cohort Study in a Peri-urban Community of Peru.Do current cost-effectiveness analyses reflect the full value of childhood vaccination in Europe? A rotavirus case study.The viral polymerase inhibitor 2'-C-methylcytidine inhibits Norwalk virus replication and protects against norovirus-induced diarrhea and mortality in a mouse model.Diversity in Rotavirus-Host Glycan Interactions: A "Sweet" Spectrum.Norovirus prevalence and estimated viral load in symptomatic and asymptomatic children from rural communities of Vhembe district, South Africa.Multiple norovirus infections in a birth cohort in a Peruvian Periurban community.Association between norovirus and rotavirus infection and histo-blood group antigen types in Vietnamese children.Progress toward norovirus vaccines: considerations for further development and implementation in potential target populations.Estimated reductions in hospitalizations and deaths from childhood diarrhea following implementation of rotavirus vaccination in Africa.Viruses in Rodent Colonies: Lessons Learned from Murine Noroviruses.Two Birds With One Stone: Estimating Population Vaccination Coverage From a Test-negative Vaccine Effectiveness Case-control Study.Molecular analysis of norovirus in specimens from children enrolled in a 1982-1986 study in Belém, Brazil: A community-based longitudinal study.Molecular analysis of norovirus in specimens from children enrolled in a 1982-1986 study in Belém, Brazil: A community-based longitudinal study.Rotavirus epidemiology 5-6 years after universal rotavirus vaccination: persistent rotavirus activity in older children and elderly.Whole genome analysis of Vietnamese G2P[4] rotavirus strains possessing the NSP2 gene sharing an ancestral sequence with Chinese sheep and goat rotavirus strains.Sustained High Effectiveness of RotaTeq on Hospitalizations Attributable to Rotavirus-Associated Gastroenteritis During 4 Years in Finland.Rotavirus vaccination and infection induce VP6-specific IgA responses.Narrowing of the Diagnostic Gap of Acute Gastroenteritis in Children 0-6 Years of Age Using a Combination of Classical and Molecular Techniques, Delivers Challenges in Syndromic Approach Diagnostics.Post-exposure antiviral treatment of norovirus infections effectively protects against diarrhea and reduces virus shedding in the stool in a mortality mouse model.Prevalence and molecular characterization of human noroviruses and sapoviruses in Ethiopia.Health Impact of Rotavirus Vaccination in Developing Countries: Progress and Way Forward.Induction of homologous and cross-reactive GII.4-specific blocking antibodies in children after GII.4 New Orleans norovirus infection.A systematic review and meta-analysis of the prevalence of norovirus in cases of gastroenteritis in developing countries.
P2860
Q26783083-D054EEEC-3627-465F-AD08-67C52DF789F5Q26853690-AA0B3192-24F3-4C7D-9F8B-534B09DC144CQ27004488-A42C0042-A107-4BB8-80F0-0881116CBB69Q27021385-7E976AAB-F68D-43AA-835C-949D0D299C5EQ30356098-9FC34ADD-4A72-4068-821E-3CE76A281EE1Q33646176-F620E3AF-293D-467F-87CD-EF6F5EBC58A5Q33654573-4A93C37C-7F32-463A-B3AB-2FD3C11CB47EQ34907018-95FFEDF8-2D64-48AB-AD34-CF6385ED7BE0Q35114054-5C429C2D-79FF-42B5-8651-7E3761FF5997Q35358176-0DA5F104-424A-4237-B9EB-6CCD723154C2Q35947992-13B815B6-E66E-4561-81F2-27A5F1708811Q35999759-A9522ED3-69A9-4E2F-8E3A-1064E7C1B4EBQ36181393-61A2BC55-40F1-4521-9319-E347421694FBQ36254157-E0585257-9E0D-407D-B4DC-3522A86CBFDEQ36373327-552A562D-1CC7-4B5B-A423-151D9A2CAC94Q36434360-A4974468-40A5-41C8-89E6-FA7EEFA51A2DQ36841045-DFA45F7C-FCE5-426E-814C-2AD1AEA8F3F5Q36933174-2F2138E1-4B08-4590-AF5C-01677F18660CQ36978368-68EFF77E-63A0-45FA-829F-C781218630C7Q37252661-DB3FF016-AD46-46FD-A158-DA4379F3FF49Q37296744-46351C0A-0B78-4A80-9B0C-B5E30ACC358AQ37398805-B660FCF7-BB66-41FE-A0F6-A50C6453FBF1Q37528428-9970D506-12F6-4D34-82A0-35754899B926Q37713694-935536D5-6509-4274-8017-317C1631A9F3Q38557262-4E04C6B6-6C32-4F4F-910C-73F006167AA2Q38612845-1AD5C3AC-19D5-4E9F-BEB4-5E6DA14DA64EQ38766728-64F1834E-F24C-4DD9-AE27-87BA06E7198BQ39676299-8D0CE45B-B5AB-4536-A0E5-ADA2C6A4BFFFQ40261280-AD058124-8D8C-4014-A7BD-B0753B4DBAE3Q40283651-693889AF-A4CE-46FB-86D7-4255F90DBEF1Q40379989-7F84DA90-D1E6-42C6-9C1E-4965CCBE1534Q40527101-AE54841C-C865-4CB0-9376-FF8E5E3635C2Q40530316-C656A2B5-825E-4329-9C9E-B1E4807DC3F1Q40608783-D304B523-7CCF-442C-8F1F-D12530C6DA71Q40640714-7FA1EF08-E430-40BA-A699-62E3E1B913BDQ40649322-80468569-0039-46AC-9AAD-C23774A9F189Q40669265-9D7B1077-4E73-4836-9ED7-6F8F6437D14CQ40722565-C1A9331F-7D6A-42F3-9A1F-4F59A75040A4Q41254719-2B3D5CAD-491D-4AF0-8A87-84A1B46A84B1Q41922889-5BBD989C-5B40-4D55-9E47-E22CD6D34852
P2860
Major reduction of rotavirus, but not norovirus, gastroenteritis in children seen in hospital after the introduction of RotaTeq vaccine into the National Immunization Programme in Finland.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Major reduction of rotavirus, ...... nization Programme in Finland.
@en
Major reduction of rotavirus, ...... nization Programme in Finland.
@nl
type
label
Major reduction of rotavirus, ...... nization Programme in Finland.
@en
Major reduction of rotavirus, ...... nization Programme in Finland.
@nl
prefLabel
Major reduction of rotavirus, ...... nization Programme in Finland.
@en
Major reduction of rotavirus, ...... nization Programme in Finland.
@nl
P2093
P2860
P921
P1476
Major reduction of rotavirus, ...... nization Programme in Finland.
@en
P2093
Leena Huhti
Maria Hemming
Marjo Salminen
Minna Paloniemi
Sirpa Räsänen
Timo Vesikari
P2860
P2888
P304
P356
10.1007/S00431-013-1945-3
P577
2013-01-30T00:00:00Z